RIGL · Rigel Pharmaceuticals Inc · Webcasts, Transcripts & Audio
$42.53
-0.39 (-0.91%)
At close · Nov 18
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$800.84M
Shares
18.83M
Volume · Nov 18
304.84K
Avg daily vol (3M)
252.93K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Rigel Pharmaceuticals Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Rigel Pharmaceuticals Inc (RIGL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Rigel Pharmaceuticals Inc (RIGL) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
Rigel Pharmaceuticals Inc (RIGL) Q3 2026 Earnings Call Transcript
Confident tone
R289 development in lower-risk MDS
Vepenu commercial launch
Commercial portfolio performance
Revenue
$80.89M
▲ 16.5% YoY Diluted EPS
$0.65
▼ 55.5% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-11-05
Rigel Pharmaceuticals Inc (RIGL) November 5, 2026 Investor Update
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Rigel Pharmaceuticals Inc (RIGL) September 15, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-10
Rigel Pharmaceuticals Inc (RIGL) September 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Capital Markets Day
Investor event
2026-08-13
Rigel Pharmaceuticals Inc (RIGL) August 13, 2026 Capital Markets Day
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Rigel Pharmaceuticals Inc (RIGL) Q2 2026 Earnings Call Transcript
Confident tone
Pipeline / R289 Development
Breast Cancer Market Opportunity
Commercial Launch Execution
Revenue
$78.70M
▼ 22.6% YoY Diluted EPS
$0.88
▼ 73.2% YoY Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Rigel Pharmaceuticals Inc (RIGL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Rigel Pharmaceuticals Inc (RIGL) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2026 Earnings Call Transcript
Confident tone
R289 pipeline in lower-risk MDS
Net product sales growth
2026 financial guidance and profitability
Revenue
$58.82M
▲ 10.3% YoY Diluted EPS
$0.44
▼ 30.2% YoY Gross margin
92.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Transcript
Confident tone
R289 pipeline in lower-risk MDS
Net product sales growth
Competitive landscape and unmet need
Revenue
$69.80M*
▲ 21.2% YoY Gross margin
91.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Rigel Pharmaceuticals Inc (RIGL) Q3 2025 Earnings Call Transcript
Confident tone
R289 development in lower-risk MDS
Olutasidenib pipeline expansion
Commercial product sales growth
Revenue
$69.46M
▲ 25.6% YoY Diluted EPS
$1.46
▲ 108.6% YoY Gross margin
93.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Rigel Pharmaceuticals Inc (RIGL) Q2 2025 Earnings Call Transcript
Revenue
$101.69M
▲ 176% YoY Diluted EPS
$3.28
Gross margin
95.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Transcript
Confident tone
R289 pipeline in MDS
Commercial portfolio of three products
Olutasidenib expansion into glioma
Revenue
$53.33M
▲ 80.6% YoY Diluted EPS
$0.63
Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Rigel Pharmaceuticals Inc (RIGL) Q4 2024 Earnings Call Transcript
Confident tone
Commercial portfolio growth and product sales
Pipeline development - R289 in lower-risk MDS
Olutasidenib collaborations and IDH1 mutant cancers
Revenue
$57.60M*
▲ 60.9% YoY Gross margin
89.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Transcript
Confident tone
Commercial growth and product sales
GAVRETO integration and transition
Pipeline development and R289
Revenue
$55.31M
▲ 96.6% YoY Diluted EPS
$0.70
Gross margin
85.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Rigel Pharmaceuticals Inc (RIGL) Q2 2024 Earnings Call Transcript
Confident tone
GAVRETO acquisition and launch
R289 pipeline in MDS
TAVALISSE commercial performance
Revenue
$36.84M
▲ 37% YoY Diluted EPS
$-0.06
Gross margin
92.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Rigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript
Confident tone
TAVALISSE demand growth
REZLIDHIA uptake
GAVRETO acquisition
Revenue
$29.53M
▲ 13.3% YoY Diluted EPS
$-0.47
Gross margin
93.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Rigel Pharmaceuticals Inc (RIGL) Q4 2023 Earnings Call Transcript
Confident tone
GAVRETO acquisition and commercial opportunity
TAVALISSE and REZLIDHIA commercial performance
Market expansion via RET testing and biomarker awareness
Revenue
$35.79M*
▼ 30.2% YoY Gross margin
89.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Rigel Pharmaceuticals Inc (RIGL) Q3 2023 Earnings Call Transcript
Revenue
$28.13M
▲ 25.5% YoY Diluted EPS
$-0.33
Gross margin
95.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Rigel Pharmaceuticals Inc (RIGL) Q2 2023 Earnings Call Transcript
Revenue
$26.89M
▼ 9.8% YoY Diluted EPS
$-0.38
Gross margin
96.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Rigel Pharmaceuticals Inc (RIGL) Q1 2023 Earnings Call Transcript
Revenue
$26.07M
▲ 55.8% YoY Diluted EPS
$-0.80
Gross margin
96.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Rigel Pharmaceuticals Inc (RIGL) Q4 2022 Earnings Call Transcript
Revenue
$51.28M*
▲ 151.3% YoY Gross margin
99.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Rigel Pharmaceuticals Inc (RIGL) Q3 2022 Earnings Call Transcript
Revenue
$22.41M
▲ 4% YoY Diluted EPS
$-1.10
Gross margin
98.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Rigel Pharmaceuticals Inc (RIGL) Q2 2022 Earnings Call Transcript
Revenue
$29.82M
▲ 13.5% YoY Diluted EPS
$-0.80
Gross margin
96.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Rigel Pharmaceuticals Inc (RIGL) Q1 2022 Earnings Call Transcript
Revenue
$16.73M
▼ 79.3% YoY Diluted EPS
$-1.60
▼ 172.7% YoY Gross margin
99.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Rigel Pharmaceuticals Inc (RIGL) Q4 2021 Earnings Call Transcript
Revenue
$20.41M*
▲ 10.6% YoY Gross margin
97.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Rigel Pharmaceuticals Inc (RIGL) Q3 2021 Earnings Call Transcript
Revenue
$21.54M
▲ 17.2% YoY Diluted EPS
$-1.20
Gross margin
99.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Rigel Pharmaceuticals Inc (RIGL) Q2 2021 Earnings Call Transcript
Revenue
$26.27M
▲ 63.9% YoY Diluted EPS
$-0.80
Gross margin
99.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2021 Earnings Call Transcript
Revenue
$81.02M
▲ 45.3% YoY Diluted EPS
$2.20
▲ 69.2% YoY Gross margin
99.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Rigel Pharmaceuticals Inc (RIGL) Q4 2020 Earnings Call Transcript
Revenue
$18.45M
▲ 19.8% YoY Gross margin
94.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Rigel Pharmaceuticals Inc (RIGL) Q3 2020 Earnings Call Transcript
Revenue
$18.39M
▼ 11.8% YoY Diluted EPS
$-0.80
Gross margin
87.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Rigel Pharmaceuticals Inc (RIGL) Q2 2020 Earnings Call Transcript
Revenue
$16.02M
▲ 53.9% YoY Diluted EPS
$-1.00
Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Rigel Pharmaceuticals Inc (RIGL) Q1 2020 Earnings Call Transcript
Revenue
$55.76M
▲ 341.7% YoY Diluted EPS
$1.30
Gross margin
22.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Rigel Pharmaceuticals Inc (RIGL) Q4 2019 Earnings Call
Revenue
$15.40M
▼ 59.3% YoY Gross margin
88.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–35 of 35 webcasts
Key facts
CIK
1034842
CUSIP
766559702
13F (30d)
182 filings
156 filers
Visit website
Investor relations